

October 29, 2025

Kidswell Bio Corporation (TSE:4584)

S-Quatre Corporation

“Treg” with “SHED”

Toward the Development of an Innovative Immune Cell Therapy — Joint Research Agreement with Tokyo University of Science —

Tokyo, October 29, 2025 - Kidswell Bio Group is engaged in the research and development of novel cell-based therapies (regenerative medicine products) utilizing stem cells from human exfoliated deciduous teeth (SHED), with the aim of developing new treatments for pediatric and rare diseases for which no effective therapies currently exist.

S-Quatre Corporation, a subsidiary of our group, has entered into a joint research agreement with Institute of Science Tokyo (Science Tokyo) to develop a novel immune cell therapy targeting autoimmune and other related diseases through the combination of Treg (regulatory T cell) and SHED.

Autoimmune diseases are a group of disorders in which the immune system erroneously attacks the body's own tissues, causing inflammation and tissue damage, such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. Tregs play a critical role as a “brakes” on such excessive immune responses, however, when the numerical or functional balance is perturbed, this regulatory mechanism fails, leading to disease onset.

In the organ transplantation, immunosuppressive drugs are indispensable to prevent immune rejection, however, lifelong administration is typically required, and side effects such as infections and organ dysfunction can significantly reduce patients' quality of life (QOL).

In recent years, cell therapies utilizing Tregs have drawn increasing global attention as a potential breakthrough solution to these challenges, and extensive research is underway worldwide. This movement was sparked by the discovery of Treg and subsequent research achievements, for which the Nobel Prize in Physiology or Medicine was awarded in 2025.

The Immunology team in the Department of Molecular Microbiology, Graduate School of Medical and Dental Sciences, Science Tokyo, has conducted research on immune-cell-based therapies for leukemia and on elucidating how immune cells contribute to the pathogenesis of autoimmune diseases and other related disorders.

The objective of this joint research is to advance Treg cell therapy toward practical application. By integrating our proprietary stem cells (SQ-SHED) with Science Tokyo's expertise and technologies in immune cell research, we aim to establish an ultimate treatment for autoimmune diseases and transplantation-induced immune rejection.

S-Quatre will continue to actively collaborate with leading-edge biotech companies and academic institutions in the world, striving to maximize the value of SQ-SHED and to pioneer new frontiers in the cell therapy field.

Disclaimer: This English translation is provided for reference purposes only. Should any discrepancies arise between this translation and the original Japanese document, the original Japanese document shall take precedence.